The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

著录项

• 来源
  《Blood: The Journal of the American Society of Hematology》 |2019年第23期|共5页
• 作者

  OSullivan Jennifer M.; Hamblin Angela; Yap Christina; Fox Sonia; Boucher Rebecca; Panchal Anesh; Alimam Samah; Dreau Helene; Howard Kieran; Ware Pauline; Cross Nicholas C. P.; McMullin Mary Frances; Harrison Claire N.; Mead Adam J.;

  展开▼
• 作者单位

  Guys &

  St Thomas Natl Hlth Serv NHS Fdn Trust Dept Haematol London England;

  Oxford Mol Diagnost Ctr Oxford England;

  Univ Birmingham Canc Res UK Clin Trials Unit Birmingham W Midlands England;

  Univ Birmingham Canc Res UK Clin Trials Unit Birmingham W Midlands England;

  Univ Birmingham Canc Res UK Clin Trials Unit Birmingham W Midlands England;

  Univ Birmingham Canc Res UK Clin Trials Unit Birmingham W Midlands England;

  Guys &

  St Thomas Natl Hlth Serv NHS Fdn Trust Dept Haematol London England;

  Oxford Mol Diagnost Ctr Oxford England;

  Oxford Mol Diagnost Ctr Oxford England;

  Oxford Mol Diagnost Ctr Oxford England;

  Wessex Reg Genet Lab Salisbury Wilts England;

  Queens Univ Dept Haematol Belfast Antrim North Ireland;

  Guys &

  St Thomas Natl Hlth Serv NHS Fdn Trust Dept Haematol London England;

  Univ Oxford Haematopoiet Stem Cell Biol Lab Oxford England;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 血液及淋巴系疾病;
• 关键词